Sitagliptin: a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. - Wikidata - awgldk - TriplyDB

Sitagliptin: a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.

Sitagliptin: a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.

http://www.wikidata.org/entity/Q34569365

about

Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus Recent Advances in Dipeptidyl-Peptidase-4 Inhibition Therapy: Lessons from the Bench and Clinical Trials Sitagliptin in the treatment of type 2 diabetes: a meta-analysis.Fixed-dose combination of sitagliptin and metformin for the treatment of type 2 diabetes.Sitagliptin/Simvastatin: a first combination tablet to treat type 2 diabetes and hypercholesterolemia--a review of its characteristics New-onset diabetes mellitus in the kidney recipient: diagnosis and management strategies.A review of the treatment of type 2 diabetes in children Dipeptidyl peptidase IV (DPPIV/CD26) inhibition does not improve engraftment of unfractionated syngeneic or allogeneic bone marrow after nonmyeloablative conditioning Interactive hemodynamic effects of dipeptidyl peptidase-IV inhibition and angiotensin-converting enzyme inhibition in humans.Association between sitagliptin adherence and self-monitoring of blood glucose.Sitagliptin/Metformin (janumet) as combination therapy in the treatment of type-2 diabetes mellitus Review of sitagliptin phosphate: a novel treatment for type 2 diabetes.Conditioning response to granulocyte colony-stimulating factor via the dipeptidyl peptidase IV-adenosine deaminase complex.Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus.Vildagliptin: a review of its use in type 2 diabetes mellitus.Selective fluorescence probes for dipeptidyl peptidase activity-fibroblast activation protein and dipeptidyl peptidase IV.Stability enhancement of drug layered pellets in a fixed dose combination tablet Combining a dipeptidyl peptidase-4 inhibitor, alogliptin, with pioglitazone improves glycaemic control, lipid profiles and beta-cell function in db/db mice.Protective effect of sitagliptin and rosuvastatin combination on vascular endothelial dysfunction in type-2 diabetes.Can access limits on sales representatives to physicians affect clinical prescription decisions? A study of recent events with diabetes and lipid drugs.Dipeptidyl-peptidase IV (DPP-IV) inhibitor delays tolerance to anxiolytic effect of ethanol and withdrawal-induced anxiety in rats.

P2860

Q24243196-9B79696F-8955-45E5-9922-6F0A06D7F8B9 Q28081569-43B21DA6-6FBD-49B0-9317-C8135ED92D71 Q34344570-C1E64620-C716-4F4D-B41C-A7AF2AA45B70 Q34620693-F32C44CA-49F0-4F40-B77D-062F9BF1B821 Q35100483-28530498-808C-462C-B8F3-BE5E388BD662 Q35153309-1FFCFED0-188F-48EB-8B6C-8DF86E55DAC3 Q35157954-94ADAEA4-DF92-49C4-BE4B-25432E36AD61 Q35693453-ED2551E3-5601-4A4A-BB89-33804AADEC1A Q35833586-FE75319E-2795-4E30-89CE-A027B3DF514D Q36228968-1B557445-E3D8-465C-9A4C-B1D2DFB776D5 Q36523423-730497C8-E01A-4538-B67C-2B5E06976441 Q36854023-3AFE1F9F-DAB6-4D28-9A82-401E7AAFCBFE Q37176935-8D19A28F-6A0A-4AAC-98B9-ACE20EC91227 Q37735838-CE397966-2048-44C5-8ABD-1C03A1102BE3 Q37801906-B5744115-7AF6-4D99-80F3-3498DA8E913B Q40134994-37437BFD-6BF6-4925-97C7-912D5792AAFD Q41988061-CB07332B-1D00-47EC-97FE-157652B169AD Q42248942-C814B2A8-AA3C-4102-BC85-8C948461A7E5 Q43182745-32AA5885-DDF9-4136-BD9D-BF78A4EE94D3 Q44902330-95CF0A18-4490-4918-92AC-62D6456B34B0 Q47830426-3C2DF7DC-789D-4450-B510-AB8D0CCBBB28

P2860

Sitagliptin: a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.

http://www.wikidata.org/entity/Q34569365

description

2006 nî lūn-bûn

@nan

2006 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Sitagliptin: a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.

@ast

Sitagliptin: a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.

@en

Sitagliptin: a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.

@nl

type

label

Sitagliptin: a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.

@ast

Sitagliptin: a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.

@en

Sitagliptin: a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.

@nl

prefLabel

Sitagliptin: a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.

@ast

Sitagliptin: a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.

@en

Sitagliptin: a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.

@nl

P1433

Q34569365-C48FF923-402B-4FC4-8BDC-E74FA21087BE

P1476

Q34569365-415BD596-83AC-4775-B9BA-71102F4E14E3

P2093

Q34569365-3E18049A-CE96-4F4A-BFCB-2E3A4691A790

Q34569365-506257E2-D00E-4137-8568-D8A86749758B

P2860

Q34569365-0892B6EA-CCE1-43B6-97B7-785267CE1055

Q34569365-0F6B4727-92DC-405B-9A5B-6AA41B866995

Q34569365-2FDE95CE-36F1-46C7-BF65-4616B9C901FD

Q34569365-31DD1697-8AFC-4060-AEDC-FB905E31BF5C

Q34569365-35F794DF-FB6A-4FF1-B4EB-43E1045C32B0

Q34569365-41A05870-A215-4E9A-B488-34A4D0C7A250

Q34569365-65C73608-15DD-42F2-8E81-F8DDFD5FFA31

Q34569365-6E3F7735-27A8-4CD5-BFE7-2E1E1A8C9966

Q34569365-737394F5-0480-4717-BFE0-2F9BC7A086D1

Q34569365-80AFC167-3E24-448F-8943-9DFDE0C67421

P304

Q34569365-C640BEA2-D8D4-47DC-83A6-9B977934071E

P31

Q34569365-F0328E78-1940-47FF-B1FC-659E10BE2FBD

P356

Q34569365-9458D00F-4D7E-4C28-AC88-581867B23F24

P407

Q34569365-CA8E687A-8DBF-4723-A649-40CCCD59C03A

P433

Q34569365-7347FCA9-2F09-4C7A-A8DD-83C4DF16E0A8

P478

Q34569365-5D1E2A80-8660-4131-B12F-66CDAAEE5C23

P577

Q34569365-F68FFC8F-0736-4B0D-A956-F8126B4BEBBE

P698

Q34569365-E31AD924-75C9-49B5-8B38-1FBD3B97EC05

P921

Q34569365-D17A34AD-9955-4FE8-B4B2-9F6E3581AA12

P356

P1433

Annals of Pharmacotherapy

P1476

Sitagliptin: a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.

@en

P2093

Erin L St Onge

http://www.w3.org/2001/XMLSchema#string

Shannon Miller

http://www.w3.org/2001/XMLSchema#string

P2860

Dipeptidyl peptidase IV inhibitors: how do they work as new antidiabetic agents?

Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes

Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses

Improved glucose tolerance in Zucker fatty rats by oral administration of the dipeptidyl peptidase IV inhibitor isoleucine thiazolidide.

Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes.

Dipeptidyl-peptidase IV (CD26)--role in the inactivation of regulatory peptides.

Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance

Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26.

Dipeptidyl peptidase IV inhibitors for the treatment of diabetes.

Inhibitors of dipeptidyl peptidase IV: a novel approach for the prevention and treatment of Type 2 diabetes?

P304

1336-1343

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1345/APH.1G665

http://www.w3.org/2001/XMLSchema#string

P407

P433

7-8

http://www.w3.org/2001/XMLSchema#string

P478

40

http://www.w3.org/2001/XMLSchema#string

P577

2006-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16868220

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes